(V016) Eagle Eye Platinum
Total Payments
$6.6M
Transactions
82
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.0M | 28 | 0 |
| 2023 | $2.8M | 42 | 0 |
| 2022 | $1.8M | 12 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 82 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| IMPROVE RCT | Philips Electronics North America Corporation | $2.5M | 0 |
| IMPROVE RCT | Philips North America LLC | $1.9M | 0 |
| IMPROVE | Philips Electronics North America Corporation | $1.8M | 0 |
| Temporal Trends, Practice Variation and Associated Outcomes with Use of Intravascular Ultrasound during Cardiovascular Intervention | Philips Electronics North America Corporation | $248,625 | 0 |
| iDissection Retrospective | Philips North America LLC | $40,731 | 0 |
| Intracoronary Acetylcholine Stability: Overcoming Barriers to Coronary Vasospasm Testing Programs | Philips Electronics North America Corporation | $30,000 | 0 |
| iDissection Retrospective (IVUS Outcomes) | Philips North America LLC | $20,000 | 0 |
Top Doctors Receiving Payments for (V016) Eagle Eye Platinum
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Washington, DC | $6.6M | 82 |
Ad
Manufacturing Companies
Product Information
- Type Device
- Total Payments $6.6M
- Total Doctors 0
- Transactions 82
About (V016) Eagle Eye Platinum
(V016) Eagle Eye Platinum is a device associated with $6.6M in payments to 0 healthcare providers, recorded across 82 transactions in the CMS Open Payments database. The primary manufacturer is Philips Electronics North America Corporation.
Payment data is available from 2022 to 2024. In 2024, $2.0M was paid across 28 transactions to 0 doctors.
The most common payment nature for (V016) Eagle Eye Platinum is "Unspecified" ($6.6M, 100.0% of total).
(V016) Eagle Eye Platinum is associated with 7 research studies, including "IMPROVE RCT" ($2.5M).